Company profile CLRB
After 39 days of this quarter the interest is at 30.0. Based on that we can calculate that during remaining 52 days it will total up to 70.0. Cellectar Biosciences expected interest is significantly lower compared to previous quarter (-67.9%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 90 | 43 -52.2% QoQ | 97 125.6% QoQ | 88 -9.3% QoQ |
| 2020 | 167 85.6% YoY 89.8% QoQ | 90 109.3% YoY -46.1% QoQ | 207 113.4% YoY 130.0% QoQ | 388 340.9% YoY 87.4% QoQ |
| 2021 | 334 100.0% YoY -13.9% QoQ | 58 -35.6% YoY -82.6% QoQ | 123 -40.6% YoY 112.1% QoQ | 77 -80.2% YoY -37.4% QoQ |
| 2022 | 84 -74.9% YoY 9.1% QoQ | 55 -5.2% YoY -34.5% QoQ | 77 -37.4% YoY 40.0% QoQ | 51 -33.8% YoY -33.8% QoQ |
| 2023 | 98 16.7% YoY 92.2% QoQ | 108 96.4% YoY 10.2% QoQ | 31 -59.7% YoY -71.3% QoQ | 218 327.5% YoY 603.2% QoQ |
| 2024 | 30 -69.4% YoY -86.2% QoQ | - | - | - |
The average 5 years interest of Cellectar Biosciences was 9.63 per week. The last year interest of Cellectar Biosciences compared to the last 5 years has changed by -6.75%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 19.73%.
There is not enough data for CLR 131 clinical trials to provide analysis
There is not enough data for CLR 131 clinical trials to provide correlation calculation
There is not enough data for CLR 131 clinical trials to provide analysis
There is not enough data for Relapsed or refractory lymphomas treatments to provide analysis
There is not enough data for Relapsed or refractory lymphomas treatments to provide correlation calculation
There is not enough data for Relapsed or refractory lymphomas treatments to provide analysis
There is not enough data for Cellectar Biosciences stock price to provide analysis
There is not enough data for Cellectar Biosciences stock price to provide correlation calculation
There is not enough data for Cellectar Biosciences stock price to provide analysis
There is not enough data for Biopharmaceutical companies developing cancer drugs to provide analysis
There is not enough data for Biopharmaceutical companies developing cancer drugs to provide correlation calculation
There is not enough data for Biopharmaceutical companies developing cancer drugs to provide analysis
There is not enough data for Cellectar Biosciences pipeline to provide analysis
There is not enough data for Cellectar Biosciences pipeline to provide correlation calculation
There is not enough data for Cellectar Biosciences pipeline to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. Cellectar Biosciences news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 121 | 172 42.1% QoQ | 116 -32.6% QoQ | 137 18.1% QoQ |
| 2020 | 116 -4.1% YoY -15.3% QoQ | 89 -48.3% YoY -23.3% QoQ | 192 65.5% YoY 115.7% QoQ | 136 -0.7% YoY -29.2% QoQ |
| 2021 | 34 -70.7% YoY -75.0% QoQ | 128 43.8% YoY 276.5% QoQ | 146 -24.0% YoY 14.1% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2022 | 178 423.5% YoY inf% QoQ | 64 -50.0% YoY -64.0% QoQ | 118 -19.2% YoY 84.4% QoQ | 153 inf% YoY 29.7% QoQ |
| 2023 | 63 -64.6% YoY -58.8% QoQ | 35 -45.3% YoY -44.4% QoQ | 86 -27.1% YoY 145.7% QoQ | 143 -6.5% YoY 66.3% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Cellectar Biosciences news was 8.53 per week. The last year interest of Cellectar Biosciences news compared to the last 5 years has changed by -36.23%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -50.9%.
After 39 days of this quarter the interest is at 100.0. Based on that we can calculate that during remaining 52 days it will total up to 233.0. Cancer treatment advancements expected interest is significantly higher compared to previous quarter (+454.8%) and same quarter last year (+288.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 21 | 76 261.9% QoQ | 123 61.8% QoQ | 25 -79.7% QoQ |
| 2020 | 54 157.1% YoY 116.0% QoQ | 58 -23.7% YoY 7.4% QoQ | 99 -19.5% YoY 70.7% QoQ | 92 268.0% YoY -7.1% QoQ |
| 2021 | 106 96.3% YoY 15.2% QoQ | 140 141.4% YoY 32.1% QoQ | 115 16.2% YoY -17.9% QoQ | 96 4.3% YoY -16.5% QoQ |
| 2022 | 54 -49.1% YoY -43.8% QoQ | 124 -11.4% YoY 129.6% QoQ | 46 -60.0% YoY -62.9% QoQ | 51 -46.9% YoY 10.9% QoQ |
| 2023 | 60 11.1% YoY 17.6% QoQ | 37 -70.2% YoY -38.3% QoQ | 47 2.2% YoY 27.0% QoQ | 42 -17.6% YoY -10.6% QoQ |
| 2024 | 100 66.7% YoY 138.1% QoQ | - | - | - |
The average 5 years interest of Cancer treatment advancements was 6.0 per week. The last year interest of Cancer treatment advancements compared to the last 5 years has changed by -19.17%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 2.97%.
There is not enough data for Cellectar Biosciences partner collaborations to provide analysis
There is not enough data for Cellectar Biosciences partner collaborations to provide correlation calculation
There is not enough data for Cellectar Biosciences partner collaborations to provide analysis
There is not enough data for Cellectar Biosciences careers to provide analysis
There is not enough data for Cellectar Biosciences careers to provide correlation calculation
There is not enough data for Cellectar Biosciences careers to provide analysis